Tan Tock Seng Hospital | Clinical Research and Innovation Office
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
750 participants in 2 patient groups
Loading...
Central trial contact
Amgen Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal